Investors
Where Innovation Meets Impact.
AI-Powered Platforms Transforming Digital Health and Driving Shareholder Value
Why Invest in AIML?
CSE: AIML
OTCQB: AIMLF
FWB: 42FB
We are pioneering the future of health intelligence by developing and commercializing advanced AI-driven technologies that unlock powerful biometric insights
Backed by a growing portfolio of proprietary technologies and a world-class leadership team, AIML is committed to delivering long-term value to shareholders while improving health outcomes across global markets.
Press Releases
Read more in Archive
September 1, 2026
AI/ML Innovations subsidiary NeuralCloud Appoints Former FDA Reviewer Dr. Mehmet Kosoglu as the Head of Regulatory Affairs
Read More
August 26, 2026
AI/ML Innovations Inc. Closes First Tranche of Private Placement
Read More
August 18, 2026
AIML Subsidiary NeuralCloud Signs Term Sheet with Island Mobile Cardiology Testing for CardioYield™ Pilot
Read More
August 14, 2026
AI/ML Innovations Inc. Announces Proposed Private Placement
Read More
August 11, 2026
AI/ML Innovations’ Subsidiary NeuralCloud Achieves ISO 13485:2016 (MDSAP) Certification
Read More
June 23, 2026
AI/ML Innovations Inc. Announces Grant of U.S. Patent Expanding Protection for AI-Driven ECG Analysis
Read More
Full Recording of 2025 Shareholder Update
AIML’s 2025 Shareholder Update from CEO & Executive Chairman, Paul Duffy, outlining key milestones from 2025 - including Product Development, Commercial Traction, and Regulatory Progress - along with the roadmap for 2026. The livestream concludes with a Q&A with the live audience.
Visit pageCorporate Governance
Board of Directors
Financials
Read more on CSE
Read more
AGM Materials
Charters & Policies
Company Structure
253.9
Million
Shares Outstanding
16
Million
Options
190.7
Million
Warrants Outstanding
460.6
Million
Fully Diluted